Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan to Grant Total of 90 Billion Yen to 6 Firms for COVID-19 Vaccine Production
Japan’s Ministry of Heath, Labor and Welfare (MHLW) said on August 7 that it will award a total of roughly 90 billion yen to six drug makers to help fund them to quickly build up manufacturing capacities for the domestic…
To read the full story
Related Article
- Health Minister Asks Makers to Boost Syringe, Needle Production for Coronavirus Vaccines
July 15, 2020
- AMED to Fund 29 New Research Projects to Develop COVID-19 Treatments, including 5 Company-Led Projects
June 24, 2020
- MHLW Starts Inviting Coronavirus Vaccine Developers after 2nd Extra Budget Passed
June 15, 2020
- Minister Mentions First Half 2021 Goal for Coronavirus Vaccination Start
June 8, 2020
- Japan Eyes Coronavirus Vaccination Launch in First Half of 2021
June 3, 2020
- 145.5 Billion Yen Allocated for COVID-19 Vaccine Production in Second Extra Budget: MHLW
May 29, 2020
REGULATORY
- LDP Panel Finalizes Honebuto Proposal on Preventive Care, Adds Obesity Focus
June 5, 2026
- Ex-GSK Japan Head Calls for End to "Obsolete" 14-Day Prescription Limit
June 5, 2026
- Trazenta Generic Outlook Remains Clouded as Court Upholds Treatment-Method Patents
June 4, 2026
- LDP Generic Caucus Wants Swift Disclosure of Company Indicator Ratings
June 4, 2026
- LDP Social Security Panel Pushes Greater Reward for Innovation: Honebuto Proposal
June 3, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…